Polymorphous Light Eruption

Cahn, Milton M.

doi:10.1001/archderm.1963.01590240080014

Cited by 23 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this long‐term follow‐up study ANA titres of ≥ 1 : 80 were found in 11·7% of 472 patients with PLE. This finding is in line with previous investigations yielding prevalence rates of elevated ANA titres in patients with PLE of between 2·9% and 19% 4–9 . However, until recently the cut‐off level for ANA positivity in healthy patients had been ill defined.…”

Section: Discussionsupporting

confidence: 91%

“…Antinuclear antibodies (ANA) as well as anti-SS-A ⁄Ro antibodies have been detected in patients with PLE in varying frequencies (2AE9-19%) but most follow-up studies so far have failed to show a progression of ANA-positive patients with PLE into LE. [4][5][6][7] However, there are also reports on the occurrence of subacute cutaneous LE (SCLE) or systemic LE (SLE) in patients with PLE with high titres of ANA and ⁄or anti-SS-A ⁄Ro antibodies and severe sun sensitivity. 8,9 The aim of our investigation was to determine the prevalence of ANA in a large cohort of patients with PLE and to examine whether ANA positivity is associated with an increased risk for development of LE during a follow-up period of up to 16 years.…”

Section: Discussionmentioning

confidence: 99%

“…This finding is in line with previous investigations yielding prevalence rates of elevated ANA titres in patients with PLE of between 2AE9% and 19%. [4][5][6][7][8][9] However, until recently the cut-off level for ANA positivity in healthy patients had been ill defined. A multicentre trial comprising 283 subjects compared the range of ANA titres in normal individuals (n = 125) with that in patients with SLE and other collagen diseases (n = 158).…”

Section: Discussionmentioning

confidence: 99%

“…Most follow-up studies concluded that PLE is not a predisposing condition for the development of LE. [4][5][6][7] However, as ANA are one of the ARA criteria for SLE it has been speculated that the presence of elevated ANA titres in patients with PLE may herald a later development of LE. 8,9 Patients with PLE in whom a diagnosis of SLE was eventually established were in general characterized by high titres of ANA (1 : 160-1 : 1280) and ⁄or anti-SS-A ⁄Ro antibodies.…”

Section: Discussionmentioning

confidence: 99%

“…Antinuclear antibodies (ANA) as well as anti‐SS‐A/Ro antibodies have been detected in patients with PLE in varying frequencies (2·9–19%) but most follow‐up studies so far have failed to show a progression of ANA‐positive patients with PLE into LE 4–7 . However, there are also reports on the occurrence of subacute cutaneous LE (SCLE) or systemic LE (SLE) in patients with PLE with high titres of ANA and/or anti‐SS‐A/Ro antibodies and severe sun sensitivity 8,9 …”

mentioning

confidence: 99%

See 4 more Smart Citations

Antinuclear antibodies in patients with polymorphic light eruption: a long-term follow-up study

Tzaneva¹,

Volc‐Platzer

Kittler

et al. 2008

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Antinuclear antibodies in patients with polymorphic light eruption: a long-term follow-up study

Tzaneva¹,

Volc‐Platzer

Kittler

et al. 2008

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Disease Associations in Polymorphous Light Eruption

Hasan¹,

Ranki²,

Jansén³

et al. 1998

Arch Dermatol

View full text Add to dashboard Cite

To examine the long-term outcome of polymorphous light eruption (PLE) in a large patient population and to evaluate associated conditions, especially lupus erythematosus, during the course of the disease.Design: A questionnaire-based follow-up study an average of 32 years after onset of PLE. The study was complemented by clinical examination of the patients with PLE similarly studied 16 years earlier or now reporting equal or worse PLE symptoms compared with the 1978-1979 followup or any symptoms suggesting an autoimmune disease.Setting: A dermatologic clinic in a university hospital.Patients: Ninety-four of the original cohort of 138 patients with PLE (87% of living patients) returned the questionnaire, and 46 (84%) of the 55 patients invited volunteered for clinical examination.Intervention: None.Main Outcome Measures: Clinical characteristics of PLE and clinical and laboratory findings referring to associated diseases, especially lupus erythematosus.Results: Twenty-three (24%; 95% confidence interval [CI], 16%-34%) of the 94 patients were cured, 48 (51%; 95% CI, 41%-62%) experienced milder symptoms, and 23 (24%; 95% CI, 16%-34%) experienced equal or worse symptoms than in the 1978-1979 follow-up. At least 1 autoimmune disease was diagnosed at some point in 14 patients (15%; 95% CI, 12%-29%) (in 13 [18%] of the female patients) and lupus erythematosus specifically in 2 (2%; 95% CI, 0%-7%) (in 2 [3%] of the female patients). The prevalence of a thyroid disease was 14% (13 patients) (95% CI, 8%-23%). Conclusion:Polymorphous light eruption is a longstanding, slowly ameliorating disease with some tendency to development of autoimmune disease or thyroid disorder, especially in female patients, but the risk for lupus erythematosus is not increased.

show abstract

Photobiology of Lupus Erythematosus

Baer

Harber²

1965

Arch Dermatol

View full text Add to dashboard Cite

Polymorphous Light Eruption

Cited by 23 publications

References 3 publications

Antinuclear antibodies in patients with polymorphic light eruption: a long-term follow-up study

Antinuclear antibodies in patients with polymorphic light eruption: a long-term follow-up study

Disease Associations in Polymorphous Light Eruption

Photobiology of Lupus Erythematosus

Contact Info

Product

Resources

About